This site needs JavaScript to work properly. Please enable it to take advantage of the complete set of features!

Skip to main page content

Add to Collections

Your saved search

Name of saved search:

Search terms:

Test search terms

Would you like email updates of new search results?

Yes
No

Email: (change)

Frequency:

Which day?

Which day?

Report format:

Send at most:

Send even when there aren't any new results

Optional text in email:

Your RSS Feed

Case Reports

. 1993 Jul 17;342(8864):173-4.

doi: 10.1016/0140-6736(93)91375-v.

Tumour-necrosis-factor antibody treatment in Crohn's disease

B Derkx, J Taminiau, S Radema, A Stronkhorst, C Wortel, G Tytgat, S van Deventer

PMID: 8101267
DOI: 10.1016/0140-6736(93)91375-v

Case Reports

Tumour-necrosis-factor antibody treatment in Crohn's disease

B Derkx et al. Lancet. 1993.

. 1993 Jul 17;342(8864):173-4.

doi: 10.1016/0140-6736(93)91375-v.

Authors

B Derkx, J Taminiau, S Radema, A Stronkhorst, C Wortel, G Tytgat, S van Deventer

PMID: 8101267
DOI: 10.1016/0140-6736(93)91375-v

No abstract available

PubMed Disclaimer

Comment in

Tumour necrosis factor inhibition by oxpentifylline and intestinal inflammation in Crohn's disease.
Bauditz J, Rückert Y, Raedler A, Nikolaus S, Lochs H, Schreiber S. Bauditz J, et al. Lancet. 1995 Jun 3;345(8962):1445. doi: 10.1016/s0140-6736(95)92635-6. Lancet. 1995. PMID: 7760641 No abstract available.

Similar articles

Maintenance treatment for Crohn's disease: has the time arrived?
Goldstein F. Goldstein F. Am J Gastroenterol. 1992 May;87(5):551-6. Am J Gastroenterol. 1992. PMID: 1350706 Review. No abstract available.
[Medical treatment of Crohn's disease].
Hiwatashi N. Hiwatashi N. Nihon Shokakibyo Gakkai Zasshi. 2000 Feb;97(2):145-52. Nihon Shokakibyo Gakkai Zasshi. 2000. PMID: 10707582 Review. Japanese. No abstract available.
[Treatment of Crohn's disease].
Beglinger Ch. Beglinger Ch. Ther Umsch. 2003 Mar;60(3):159-63. doi: 10.1024/0040-5930.60.3.159. Ther Umsch. 2003. PMID: 12693319 Review. German.
Chimeric monoclonal antibody cA2 to tumor necrosis factor alpha for Crohn's disease.
Bauditz J, Lochs H, Schreiber S. Bauditz J, et al. N Engl J Med. 1998 Jan 29;338(5):334. doi: 10.1056/NEJM199801293380515. N Engl J Med. 1998. PMID: 9446035 No abstract available.
Case report: combination therapy with granulocyte apheresis and infliximab for refractory Crohn's disease.
González Carro P, Pérez Roldán F, Roncero García Escribano O, Lafuente R, Legaz Huidobro ML, Amigo Echenagusía A. González Carro P, et al. J Clin Apher. 2006 Dec;21(4):249-51. doi: 10.1002/jca.20093. J Clin Apher. 2006. PMID: 16607627 No abstract available.

See all similar articles

Cited by

Tumour necrosis factor and Crohn's disease.
Van Deventer SJ. Van Deventer SJ. Gut. 1997 Apr;40(4):443-8. doi: 10.1136/gut.40.4.443. Gut. 1997. PMID: 9176068 Free PMC article. Review. No abstract available.
The cytokine network in rheumatoid arthritis: definition of TNF alpha as a therapeutic target.
Feldmann M. Feldmann M. J R Coll Physicians Lond. 1996 Nov-Dec;30(6):560-70. J R Coll Physicians Lond. 1996. PMID: 8961212 Free PMC article. Review. No abstract available.
Efficiency of Orexin-A for Inflammatory Flare and Mucosal Healing in Experimental Colitis: Comparison with the Anti-TNF Alpha Infliximab.
Blais A, Lan A, Blachier F, Benamouzig R, Jouet P, Couvineau A. Blais A, et al. Int J Mol Sci. 2023 May 31;24(11):9554. doi: 10.3390/ijms24119554. Int J Mol Sci. 2023. PMID: 37298505 Free PMC article.
Inflammatory bowel disease: past, present, and future.
Sands BE. Sands BE. J Gastroenterol. 2007 Jan;42(1):16-25. doi: 10.1007/s00535-006-1995-7. Epub 2007 Feb 16. J Gastroenterol. 2007. PMID: 17322989 Free PMC article. Review.
Nonobstructing Crohn's Disease.
Achkar JP, Hanauer SB. Achkar JP, et al. Curr Treat Options Gastroenterol. 1999 Apr;2(2):134-143. doi: 10.1007/s11938-999-0041-2. Curr Treat Options Gastroenterol. 1999. PMID: 11096584

See all "Cited by" articles

Publication types

Actions
Actions

MeSH terms

Actions
Actions
Actions
Actions
Actions
Actions
Actions
Actions
Actions
Actions
Actions
Actions

Substances

Actions
Actions
Actions
Actions
Actions
Actions

LinkOut - more resources

Full Text Sources
- Elsevier Science
- Ovid Technologies, Inc.
Other Literature Sources
- The Lens - Patent Citations Database
Medical
- MedlinePlus Health Information